MannKind Corp

MannKind Corp

Health CarePharmaceuticals & Biotechnology
  • Price (USD)5.09
  • Today's Change-0.21 / -3.96%
  • Shares traded275.36k
  • 1 Year change+164.42%
  • Beta1.8615
Data delayed at least 15 minutes, as of Oct 15 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

  • Revenue in USD (TTM)74.51m
  • Net income in USD-86.11m
  • Incorporated1991
  • Employees241.00
  • Location
    MannKind Corp30930 Russell Ranch Rd Ste 300WESTLAKE VILLAGE 91362-7379United StatesUSA
  • Phone+1 (818) 661-5000
  • Fax+1 (302) 636-5454
  • Websitehttp://www.mannkindcorp.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MNKD:NMQ since
Qrumpharma IncDeal completed07 Dec 202007 Dec 2020Deal completed72.54%12.55m
Data delayed at least 15 minutes, as of Oct 15 2021 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Kura Oncology Inc0.00-114.29m1.19bn111.00--2.14-----1.84-1.840.008.430.00----0.00-24.37-28.85-25.45-30.79------------0.00-------41.95--102.35--
Arcturus Therapeutics Holdings Inc8.70m-163.04m1.20bn118.00--3.92--137.89-6.38-6.380.346511.610.0291--3.4973,720.34-54.46-28.40-64.58-34.25-----1,874.18-166.62----0.1671---54.12---177.59--57.28--
Zymeworks Inc20.74m-222.57m1.20bn425.00--3.73--58.02-4.35-4.350.4056.950.0385--1.7358,416.90-41.26-36.34-48.23-43.72-----1,073.23-220.72----0.0004--31.8432.16-24.15--49.00--
ImmunoGen, Inc.136.64m-55.78m1.20bn79.00--16.94--8.81-0.2863-0.28630.7180.34190.4785--48.851,729,633.00-19.53---30.99-------40.82-----1.870.0158--60.81--57.39------
MacroGenics Inc118.58m-129.34m1.21bn370.00--3.72--10.17-2.26-,491.90-34.33-31.27-40.56-35.9140.14---109.07-110.935.16--0.00--63.400.786514.54---8.48--
Tango Therapeutics Inc0.00-1.13m1.23bn----1.86-----0.0529-0.05290.007.550.00-------1.34---1.35--------------0.00--------------
Agenus Inc68.55m-225.94m1.24bn359.00------18.06-1.12-1.120.3432-1.020.3626--7.59190,933.10-120.49-86.35-548.63-152.9294.91---332.29-206.84---2.60-----41.2428.86-67.92---0.708--
Generation Bio Co0.00-101.43m1.24bn100.00--2.84-----1.97-1.970.007.680.00----0.00-24.68---25.47--------------0.00-------31.32------
MannKind Corporation74.51m-86.11m1.27bn241.00------17.05-0.3625-0.36250.3143-0.73530.41915.1312.59309,174.30-48.43-36.78-75.80-985.2961.0959.15-115.56-54.822.85-2.272.81--3.34---10.28---14.19--
Sangamo Therapeutics Inc137.72m-135.26m1.27bn413.00--2.85--9.23-0.9464-0.94640.96683.070.1592--22.03333,450.40-15.64-18.29-18.05-20.99-----98.24-114.02----0.00--15.3924.48-27.12--43.58--
Vaxcyte Inc0.00-86.65m1.27bn58.00--4.00-----1.69-1.690.006.100.00----0.00-22.38---24.73-------------170.910.00-------77.46------
Atara Biotherapeutics Inc7.42m-317.78m1.28bn558.00--3.87--172.67-3.63-3.630.08483.910.0168----16,983.98-71.82-61.38-83.15-67.88-----4,281.64------0.00-------5.38--73.15--
Nurix Therapeutics Inc29.04m-99.41m1.29bn135.00--3.42--44.29-2.39-2.390.70068.420.0642--6.41215,133.30-21.97---24.45-------342.27------0.00---42.73---99.28------
Coherus Biosciences Inc394.65m-165.21m1.30bn311.00--8.32--3.29-2.31-2.314.882.040.52761.342.511,244,943.00-22.08-25.67-30.61-34.6388.63---41.86-34.532.16-6.220.7222--33.6373.7647.21--3.24--
COMPASS Pathways PLC0.00-65.74m1.34bn61.00--4.10-----1.78-1.780.007.850.00----0.00-31.90---32.95-------------3.660.00-------207.64------
Sundial Growers Inc37.00m-260.51m1.35bn394.00--1.24--36.52-0.6127-0.61270.03640.53070.05340.87055.0193,920.53-37.61---40.94--8.49---704.27--13.34-0.5470.0009---4.16---44.57------
Data as of Oct 15 2021. Currency figures normalised to MannKind Corp's reporting currency: US Dollar USD

Institutional shareholders

30.29%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202118.75m7.51%
SSgA Funds Management, Inc.as of 30 Jun 202115.66m6.27%
The Vanguard Group, Inc.as of 30 Jun 202112.49m5.00%
Avoro Capital Advisor LLCas of 30 Jun 20218.63m3.46%
Fidelity Management & Research Co. LLCas of 30 Jun 20214.45m1.78%
Geode Capital Management LLCas of 30 Jun 20214.23m1.69%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 20213.24m1.30%
Emerald Mutual Fund Advisers Trustas of 30 Jun 20212.88m1.15%
Emerald Advisers LLCas of 30 Jun 20212.83m1.13%
Millennium Management LLCas of 30 Jun 20212.49m1.00%
More ▼
Data from 30 Jun 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.